id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-303893-47lxq8pi	Jalkanen, Juho	Interferon beta-1a for COVID-19: critical importance of the administration route	2020-06-12		.txt	text/plain	1276	70	45	Interferon beta-1a for COVID-19: critical importance of the administration route Juho Jalkanen 1 , Maija Hollmén 2 and Sirpa Jalkanen 2* Type I interferons, especially IFN-beta, have been appointed as potential leading therapeutics to tackle severe COVID-19 and are currently being evaluated in REMAP-CAP and the WHO's Solidarity Trial. We wish to highlight the differences of these two treatment methods and also other crucial aspects of IFN-beta treatment for COVID-19 and acute respiratory distress syndrome (ARDS). Nonetheless, the purpose of i.v. administered IFN-beta for the treatment of COVID-19 and ARDS is to maximise bioavailability of the drug at the lung vasculature, as well as other vascular beds. There are a limited number of direct studies on the timing of immunomodulatory treatments such as IFN-beta, but given our basic understanding of human biology and viral defence, we suggest that IFN-beta should be given early to COVID-19 patients.	./cache/cord-303893-47lxq8pi.txt	./txt/cord-303893-47lxq8pi.txt